1.
Oral high-dose sucrosomial iron vs intravenous iron in sideropenic anemia patients intolerant/refractory to iron sulfate: a multicentric randomized study
Giordano G, Napolitano M, Di Battista V, Lucchesi A
Annals of hematology. 2020
Abstract
Iron deficiency anemia is among the most frequent causes of disability. Intravenous iron is the quickest way to correct iron deficiency, bypassing the bottleneck of iron intestinal absorption, the only true mechanism of iron balance regulation in human body. Intravenous iron administration is suggested in patients who are refractory/intolerant to oral iron sulfate. However, the intravenous way of iron administration requires several precautions; as the in-hospital administration requires a resuscitation service, as imposed in Europe by the European Medicine Agency, it is very expensive and negatively affects patient's perceived quality of life. A new oral iron formulation, Sucrosomial iron, bypassing the normal way of absorption, seems to be cost-effective in correcting iron deficiency anemia at doses higher than those usually effective with other oral iron formulations. In this multicentric randomized study, we analyze the cost-effectiveness of intravenous sodium ferrigluconate vs oral Sucrosomial iron in patients with iron deficiency anemia refractory/intolerant to oral iron sulfate without other interfering factors on iron absorption.
2.
Reduced insulin need in patients with type 2 diabetes mellitus (T2DM) with iron deficiency anemia treated with sucrosomial iron vs intravenous sodium ferrigluconate. Multicentric prospective study
Giordano G, Parente A, Gigli R, Magri M, Berardi G, Carabellese B, D’Amico F, Luciano L, Fratangelo R, Niro G, et al
Haematologica. 2016;101((s1)):848.. pb2134.
3.
Oral high dose liposomial iron vs intravenous iron in sideropenic anemia patients intolerant/refractory to iron sulphate. Multicentric randomized study
Giordano G, A Parente A, Gigli R, Magri M, Berardi G, Carabellese B, d’Amico F, Luciano L, Fratangelo R, NiroG, et al
Haematologica. 2016;101((s1)):613.. e1484.
4.
Liposomial iron improves fatigue in patients with myelodysplastic syndromes as refractory anemia. Multicentric study
Giordano G, d'Amico F, Commatteo A, Berardi G, Berardi D, Carabellese B, Gigli R, Magri M, Licianci A, di Marzio L
Haematologica. 2015;100((S1)):777.. Abstract no. PB1984.
5.
Oral high dose liposomial iron support is safe, fast, well tolerated and cost-effective as intravenous iron in sideropenic anemia. Multicentric randomized study
Giordano G, d’Amico F, Commatteo A, Berardi G, Berardi D, Carabellese B, Gigli R, Magri M, Licianci A, di Marzio L
Haematologica. 2015;100((S1)):133.. Abstract no. P382.
6.
Erythropoietin alpha vs biosimilar erythropoietin alpha plus lipofer and B12 and folates in patients with refractory anemia. two center prospectic study abstract
Giordano G, Mondello P, Tambaro1 R, Perrotta N, DÆAmico F, Sticca G, Di Falco C
Haematologica. 2012;97((S1):):142. Abstract No. 0353.
7.
Erythropoietin plus danazole, prednisone, B12 and folate in refractory cytopenia with multilineage dysplasia. Monocentric prospective study
Giordano G, Mondello P, Tambaro R, De Maria M, D’Amico F, Sticca G, Di Falco C
Haematologica. 2011;96((6, Suppl 2):):351. Abstract No. 0843.
8.
Intravenous iron support vs oral liposomial iron support in patients wit refractory anemia treated with EPOa. Monocentric prospective study
Giordano G, Mondello P, D’Amico F, De Maria M, Sticca G, Di Falco C
Haematologica. 2011;96((6, Suppl 2):):517. Abstract No. 1262.